转移性乳腺癌

Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21:257-272.

• 摘要

Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993;55:891-903.

• 摘要

Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996,14:2197-2205.

• 摘要

Briest S, Stearns V. Chemotherapeutic strategies for advanced breast cancer. Oncology (Williston Park). 2007;21:1325-1335.

• 摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. http://www.nccn.org/ (last accessed 17 May 2017).

• 全文

Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001.

Kardinal C, Cole J. Breast cancer. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.

Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010;123:9-24.

• 摘要

Swain S, Kim S, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-471.

• 摘要

Cianfrocca M, Gradishar WJ. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. J Natl Compr Canc Netw. 2007;5:673-675.

• 摘要

Conlin AK, Seidman AD. Point: combination versus single-agent chemotherapy: the argument for sequential single agents. J Natl Compr Canc Netw. 2007;5:668-672.

• 摘要

1.  Edge SB, Byrd DR, Brookland RK, et al (eds). AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.

2.  Leone BA, Romero A, Rabinovich MG, et al. Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis: the GOCS (Grupo Oncologico Cooperativo del Sur) experience. Am J Clin Oncol. 1988,11:618-622.

• 摘要

3.  Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21:257-272.

• 摘要

4.  Althuis MD, Dozier JM, Anderson WF, et al. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34:405-412.

• 全文
• 摘要

5.  Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993;55:891-903.

• 摘要

6.  Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533-543.

• 摘要

7.  Glass AG, Lacey JV Jr, Carreon JD, et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99:1152-1161.

• 摘要

8.  Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.

• 摘要

9.  American Cancer Society. Cancer facts and figures 2014. http://www.cancer.org (last accessed 17 May 2017).

• 全文

10.  Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996,14:2197-2205.

• 摘要

11.  Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003;68:953-964.

• 摘要

12.  Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: questions answered, questions remaining. Hematol Oncol Clin North Am. 2007;21:341-367.

• 摘要

13.  van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.

• 摘要

14.  Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355:560-569.

• 全文
• 摘要

15.  Chen P, Liang J, Wang Z, et al. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res. 2008;14:5931-5937.

• 全文
• 摘要

16.  Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497-506.

• 全文
• 摘要

17.  Carlson RW, Brown E, Burstein HJ, et al. NCCN task force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw. 2006,4(suppl 1):S1-S26.

• 摘要

18.  Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology. 1994;24:41-47.

• 摘要

19.  van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.

• 全文
• 摘要

20.  Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.

• 全文
• 摘要

21.  Benusiglio PR, Malka D, Rouleau E, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet. 2013;50:486-489.

• 摘要

22.  Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549.

• 摘要

23.  Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-524.

• 全文
• 摘要

24.  Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006;24:2261-2267.

• 全文
• 摘要

25.  Driouch K, Landemaine T, Sin S, et al. Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis. Clin Exp Metastasis. 2007;24:575-585.

• 摘要

26.  Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. J Clin Oncol. 2016;34:1208-1216.

• 全文
• 摘要

27.  Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25:5906-5911.

• 全文
• 摘要

28.  Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97:715-723.

• 全文
• 摘要

29.  Deck MD, Henschke C, Lee BC, et al. Computed tomography versus magnetic resonance imaging of the brain. A collaborative interinstitutional study. Clin Imaging. 1989;13:2-15.

• 摘要

30.  Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am. 2007;45:669-676.

• 摘要

31.  Quattrocchi CC, Piciucchi S, Sammarra M, et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (Torino). 2007;112:1049-1059.

• 摘要

32.  Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007;5(suppl 1):S1-S22.

• 摘要

33.  Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28:16-33.

• 全文
• 摘要

34.  Briest S, Stearns V. Chemotherapeutic strategies for advanced breast cancer. Oncology (Williston Park). 2007;21:1325-1335.

• 摘要

35.  Cahan WG, Woodward HQ, Highinbotham NL, et al. Sarcoma arising in irradiated bone: report of eleven cases. Cancer. 1948;1:3-29.

36.  Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol. 2007;18(suppl 8):viii18-viii25.

• 摘要

37.  Omuro AM, Leite CC, Mokhtari K, et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006;5:937-948.

• 摘要

38.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. http://www.nccn.org/ (last accessed 17 May 2017).

• 全文

39.  Crooks V, Waller S, Smith T, et al. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:M139-M144.

• 摘要

40.  British Geriatrics Society. Comprehensive Geriatric Assessment (CGA) and why it is done? February 2016. http://www.bgs.org.uk/ (last accessed 17 May 2017).

• 全文

41.  Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457-3465.

• 全文
• 摘要

42.  Hoppe S, Rainfray M, Fonck M, et al. Functional decline in older patients with cancer receiving first-line chemotherapy. J Clin Oncol. 2013;31:3877-3882.

• 全文
• 摘要

43.  Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012;30:1829-1834.

• 全文
• 摘要

44.  Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001.

45.  Rossi S, Basso M, Strippoli A, et al. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer. 2015;15:307-312.

• 摘要

46.  Van Poznak C, Somerfield MR, Bast RC, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2015;33:2695-2704.

• 全文
• 摘要

47.  Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010;107:85-91.

• 全文
• 摘要

48.  Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomised trials involving 31,510 women. J Clin Oncol. 1998;16:3439-3460.

• 摘要

49.  Kardinal C, Cole J. Breast cancer. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.

50.  Rugo HS, Rumble B, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34:3069-3103.

• 全文
• 摘要

51.  Carlini P, Bria E, Giannarelli D, et al. Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert opinion on investigational drugs. Expert Opin Investig Drugs. 2007;16:1023-1036.

• 摘要

52.  Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010;123:9-24.

• 摘要

53.  Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009;(4):CD003370.

• 全文
• 摘要

54.  Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomised group efficacy and tolerability study. J Clin Oncol. 2000;18:3748-3757.

• 摘要

55.  Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicentre randomised trial. J Clin Oncol. 2000;18:3758-3767.

• 摘要

56.  Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101-2109.

• 摘要

57.  Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole (Femara) versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-2606.

• 摘要

58.  Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35.

• 全文
• 摘要

59.  Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936.

• 摘要

60.  Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the Phase II FIRST Study. J Clin Oncol. 2015;33:3781-3787.

• 全文
• 摘要

61.  Robertson JF, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2017;388:2997-3005.

• 摘要

62.  Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-529.

• 全文
• 摘要

63.  Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209-219.

• 全文
• 摘要

64.  Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439.

• 摘要

65.  Valachis A, Mauri D, Polyzos NP, et al. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Oncol Hematol. 2010;73:220-227.

• 摘要

66.  Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998;16:994-999.

• 摘要

67.  Boccardo F, Rubagotti A, Perotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol.1994;5:337-342.

• 摘要

68.  Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first-line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1997;44:201-210.

• 摘要

69.  Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada clinical trials group trial MA1. Breast Cancer Res Treat. 1997;44:211-215.

• 摘要

70.  Wolff AC, Hammond EH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013.

• 全文
• 摘要

71.  Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:2078-2099.

• 全文
• 摘要

72.  Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.

• 摘要

73.  Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014;(6):CD006242.

• 全文
• 摘要

74.  Pivot X, Gligorov J, Müller V, et al; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962-970.

• 摘要

75.  Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13:869-878.

• 摘要

76.  Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with transtuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T. J Clin Oncol. 2007;25(18S):33s.

77.  Baselga J, Cortés J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.

• 全文
• 摘要

78.  Swain S, Kim S, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-471.

• 摘要

79.  Swain SM, Baselga J, Kim SB, et al; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.

• 全文
• 摘要

80.  Drucker AM, Wu S, Dang CT, et al. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat. 2012;135:347-354.

• 摘要

81.  Yip AY, Tse LA, Ong EY, et al. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs. 2010;21:487-493.

• 摘要

82.  Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.

• 全文
• 摘要

83.  Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30:1426-1447.

• 摘要

84.  Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30:2585-2592.

• 摘要

85.  Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013;31:1947-1953.

• 全文
• 摘要

86.  Burstein HJ, Cirrincione CT, Barry WT, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014;32:3959-3966.

• 摘要

87.  Mackey JR, Kaufman B, Clemens M, et al. Trastuzumab prolongs progression-free survival in hormone dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2006;100(suppl 1):A3.

88.  Verma S, Miles D, Gianni L, et al; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.

• 全文
• 摘要

89.  Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732-742.

• 全文
• 摘要

90.  Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31:1157-1163.

• 全文
• 摘要

91.  von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009;27:1999-2006.

• 全文
• 摘要

92.  Gori S, Montemurro F, Spazzapan S, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol. 2012;23:1436-1441.

• 全文
• 摘要

93.  Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.

• 摘要

94.  Krop IE, Kim SB, González-Martín A, et al; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689-699.

• 摘要

95.  Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743-754.

• 摘要

96.  Cardoso F, Bedard PL, Winer EP, et al; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009;101:1174-1181.

• 全文
• 摘要

97.  Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;(2):CD003372.

• 全文
• 摘要

98.  Chlebowski RT, Smalley RV, Weiner JM, et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. Br J Cancer. 1989;59:227-230.

• 摘要

99.  Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol. 1998;16:3720-3730.

• 摘要

100.  Cianfrocca M, Gradishar WJ. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. J Natl Compr Canc Netw. 2007;5:673-675.

• 摘要

101.  Conlin AK, Seidman AD. Point: combination versus single-agent chemotherapy: the argument for sequential single agents. J Natl Compr Canc Netw. 2007;5:668-672.

• 摘要

102.  O’Shaughnessy J, Gradishar WJ, Bhar P, et al. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat. 2013;138:829-837.

• 全文
• 摘要

103.  O'Brien ME, Wigler N, Inbar M, et al; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.

• 摘要

104.  Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-923.

• 摘要

105.  Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.

• 全文
• 摘要

106.  Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217.

• 全文
• 摘要

107.  Coleman R, Body JJ, Aapro M, et al; ESMO Guidelines Working Group. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2014;25(suppl 3):iii124-137.

• 全文
• 摘要

108.  Theriault RL, Biermann JS, Brown E, et al. NCCN task force report: bone health and cancer care. J Natl Compr Canc Netw. 2006;4(suppl 2):S1-S20.

• 摘要

109.  Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221-1227.

• 全文
• 摘要

110.  Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132-5139.

• 摘要

111.  Campbell-Baird C, Lipton A, Sarkeshik M, et al. Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases. Commun Oncol. 2010;7:85-89.

112.  National Institute for Health and Care Excellence. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. October 2012. http://www.nice.org.uk (last accessed 17 May 2017).

• 全文

113.  Danielson B, Winget M, Gao Z, et al. Palliative radiotherapy for women with breast cancer. Clin Oncol (R Coll Radiol). 2008;20:506-512.

• 摘要

114.  Souchon R, Wenz F, Sedlmayer F, et al; German Society of Radiation Oncology (DEGRO). DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol. 2009;185:417-424.

• 摘要

115.  Ruiterkamp J, Voogd AC, Bosscha K, et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat. 2010;120:9-16.

• 摘要

116.  Stebbing J, Ngan S. Breast cancer (metastatic) (updated). BMJ Clinical Evid. September 2010. http://clinicalevidence.bmj.com/ (last accessed 17 May 2017).

• 全文

117.  O'Shaughnessy J. BSI-201 phase II data in metastatic triple-negative breast cancer. Plenary Session, ASCO Annual Meeting, 31 May 2009.

118.  Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013;141:437-446.

• 全文
• 摘要

119.  Diéras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. San Antonio Breast Cancer Symposium, San Antonio, TX; December 2010. Abstract P3-14-01.

120.  Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.

• 全文
• 摘要

121.  Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plub placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol. 2007;25(18s):A1003.

122.  Fong PC, Boss, DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.

• 全文
• 摘要

123.  Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128-2135.

• 摘要

124.  Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.

• 全文
• 摘要